Skip to content
MenuOpen navigation menu

Real moms, real GLP-1 talk

Pregnant While Taking a GLP-1: What the Evidence Can Tell Us

Found out you're pregnant on Ozempic, Wegovy or Zepbound, or planning to be? What the drug labels and the 2026 pregnancy-outcome data actually say.

Written by — editorial research, not medical advice
On this page

A positive test changes the next step

If I had a positive pregnancy test while taking a GLP-1, I would contact the prescribing team and my obstetric clinician promptly with the exact medication, dose and last-dose date. For Wegovy used for weight reduction or cardiovascular risk reduction, the label says to discontinue when pregnancy is recognized1. An unexpected exposure deserves a specific care plan, rather than a conclusion about the pregnancy from an internet headline.

I would keep two questions separate: whether to continue a medicine during pregnancy, and what an earlier exposure means, which is the worry behind most "Ozempic babies" headlines. The observational studies discussed below help with the second question. They do not establish that continuing treatment is safe, or predict an individual baby's outcome.

What the label can and cannot tell me

Wegovy's pregnancy warning reflects animal findings and the lack of adequate human data. Weight loss offers no benefit during pregnancy and may cause fetal harm. The label distinguishes its weight-management and cardiovascular indications from MASH treatment, where the clinician must weigh potential benefit against fetal risk1. I would not turn that specialist exception into permission to continue a weight-loss prescription.

If I also had diabetes, I would ask immediately about a pregnancy-appropriate glucose-management plan. Stopping one medicine does not remove the need to manage blood sugar. The pregnancy literature is complicated partly because diabetes, glucose control and other health factors can themselves affect outcomes2. My medication list and reason for treatment matter as much as the brand name.

The newer human evidence is cautiously reassuring

A 2026 meta-analysis combined six observational studies, including 43,577 women exposed around conception. It found no statistically significant increase in major congenital malformations compared with unexposed pregnancies. The authors explicitly caution that these findings do not prove safety3. I would read that as useful evidence for a clinical conversation, rather than a guarantee.

Another 2026 review included seven cohorts and more than 40,000 exposed pregnancies. It also found no statistically significant increase in major malformations overall, but reported an association with urinary malformations based on unadjusted data. Its authors considered residual confounding a likely explanation and rated the certainty of the evidence low4. That qualification belongs beside the reassuring result.

The two reviews may include overlapping pregnancies; I would not add their totals together as independent confirmations. A broader systematic review likewise found no consistent signal in adjusted early-exposure studies while emphasizing limited evidence for continued treatment throughout pregnancy5. None of these findings answers every question about medicine, dose, timing or longer-term development.

What I would prepare for the appointment

I would write down the generic and brand names, formulation, prescribed dose, date of the last dose, positive-test date and any other medicines or supplements. If the product were compounded, I would bring the pharmacy label too. I would not assume evidence about one branded medicine precisely describes every compounded preparation.

I would ask who will coordinate the prescribing and pregnancy care, what to do before the next scheduled dose, and whether any additional follow-up is appropriate for my circumstances. I would also ask about the pregnancy exposure registry described in the Wegovy label1. Reporting an exposure helps collect information; it does not replace care.

Planning ahead is a different conversation

For a planned pregnancy or fertility treatment, I would start from the label: Wegovy's specifies stopping at least two months beforehand for weight or cardiovascular-risk treatment because semaglutide remains in the body for a long time1. Zepbound and birth control raise a separate issue from semaglutide's pregnancy washout, so I would ask about both if a switch were possible. Either way, I would confirm instructions for the exact medicine rather than apply that interval to the whole GLP-1 class.

I would also review contraception and any planned switch or dose increase. After delivery, breastfeeding and postpartum treatment each need their own assessment. I would leave with written instructions for my situation, including whom to contact if pregnancy happens sooner than planned.

Frequently asked questions

Is it dangerous that I got pregnant while taking a GLP-1?

Early-exposure studies have not shown a statistically significant increase in major malformations overall, but the evidence is observational and low certainty; one review reported an unadjusted urinary-malformation signal. This does not prove safety or predict an individual outcome. Contact your prescribing and obstetric teams promptly. Wegovy used for weight or cardiovascular-risk treatment should be discontinued when pregnancy is recognized, per its label.

What should I actually do if I find out I'm pregnant while on a GLP-1?

Contact your obstetric and prescribing teams promptly with the exact product, indication and last dose. Wegovy used for weight or cardiovascular-risk treatment should be discontinued when pregnancy is recognized; its MASH indication has different benefit-risk wording. If you take a GLP-1 for diabetes, arrange a pregnancy-appropriate glucose-management plan with your clinician rather than leaving diabetes untreated.

Can I keep taking a GLP-1 if it's still helping me lose weight in early pregnancy?

Continuing weight-loss treatment during pregnancy is not recommended. Weight reduction offers no benefit in pregnancy, and animal studies indicate potential fetal harm. Follow the exact product and indication’s labeling with your obstetric and prescribing teams; Wegovy’s MASH indication has separate benefit-risk wording.

References

  1. Novo Nordisk Inc. (2026). WEGOVY (semaglutide) injection and tablets — Prescribing Information, sections 8.1 Pregnancy (including the pregnancy exposure registry) and 8.3 Females and Males of Reproductive Potential (label revised 6/2026). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. Drummond RF, Seif KE, Reece EA (2025). Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. American Journal of Obstetrics and Gynecology. https://pubmed.ncbi.nlm.nih.gov/39181497/
  3. Liu X, Xiong B, Yang R, Wang H, Liu Y (2026). Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis. Endocrine Connections. https://pubmed.ncbi.nlm.nih.gov/42447044/
  4. Uysal N, Horoz E, Gungor M, et al. (2026). Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/42420519/
  5. Ozbek L, Shah E, Al-Shiab R, et al. (2026). Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/41885132/

One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. Pregnancy planning and breastfeeding need advice for the exact medicine and formulation. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.